Menzies AM - Search Results

1

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S. Menzies AM, et al. Aust Fam Physician. 2015 Dec;44(12):875-6. Aust Fam Physician. 2015. PMID: 27505912 No abstract available.

2

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF. Long GV, et al. Among authors: menzies am. J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559

3

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Menzies AM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052. Epub 2012 Apr 24. Clin Cancer Res. 2012. PMID: 22535154

4

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr, Lebowitz PF, Kefford RF, Long GV. Carlino MS, et al. Among authors: menzies am. Eur J Cancer. 2013 Jan;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 14. Eur J Cancer. 2013. PMID: 22981500 Clinical Trial.

5

BRAF inhibitor activity in V600R metastatic melanoma.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Klein O, et al. Among authors: menzies am. Eur J Cancer. 2013 Mar;49(5):1073-9. doi: 10.1016/j.ejca.2012.11.004. Epub 2012 Dec 10. Eur J Cancer. 2013. PMID: 23237741

6

Dabrafenib and its potential for the treatment of metastatic melanoma.

Menzies AM, Long GV, Murali R. Menzies AM, et al. Drug Des Devel Ther. 2012;6:391-405. doi: 10.2147/DDDT.S38998. Epub 2012 Dec 11. Drug Des Devel Ther. 2012. PMID: 23251089 Free PMC article. Review.

7

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Long GV. Wilmott JS, et al. Among authors: menzies am. Br J Cancer. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12. Br J Cancer. 2013. PMID: 23403819 Free PMC article.

8

BRAF inhibitor activity in V600R metastatic melanoma--response.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Klein O, et al. Among authors: menzies am. Eur J Cancer. 2013 May;49(7):1797-8. doi: 10.1016/j.ejca.2013.02.010. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490649 No abstract available.

9

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Menzies AM, Kefford RF, Long GV. Menzies AM, et al. Pigment Cell Melanoma Res. 2013 Sep;26(5):611-5. doi: 10.1111/pcmr.12132. Epub 2013 Jul 19. Pigment Cell Melanoma Res. 2013. PMID: 23795808

10

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.

Menzies AM, Long GV. Menzies AM, et al. Eur J Cancer. 2013 Oct;49(15):3229-41. doi: 10.1016/j.ejca.2013.06.027. Epub 2013 Jul 16. Eur J Cancer. 2013. PMID: 23870385 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters